Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 348

Roche’s Acquisition of InterMune Triggered by Pirfenidone Breakthrough Therapy Designation, says GlobalData Analyst

Posted by fidest press agency su sabato, 18 ottobre 2014

londonLONDON, UK (GlobalData), Adam Dion, GlobalData’s Analyst covering Healthcare Industry Dynamics, says:“Roche’s recent acquisition of InterMune gives the former the rights to pirfenidone, InterMune’s oral respiratory therapy for Idiopathic Pulmonary Fibrosis (IPF). Pirfenidone is approved for marketing in Canada and 30 European countries under the brand name Esbriet, and in Japan and South Korea where it is marketed by Shionogi as Pirespa. GlobalData forecasts sales of Esbriet to reach $1.5 billion by 2019, with long-term cash flows of $12 billion and an overall net present value of $6.7 billion, assuming US generic entry in November 2026.“There are no known causes of IPF, and there are currently no approved therapies in the US for the condition, leaving lung transplantation as the only option to extend patient life. However, InterMune hopes to change that, having just received breakthrough therapy designation from the US Food and Drug Administration (FDA) in July for pirfenidone, based on results from the Phase III ASCEND trial. The FDA has stated that it will make its final decision on the application by late November. Following the organization’s previous rejection of pirfenidone, this breakthrough designation was clearly the sign that Roche was waiting for before pulling the trigger on the purchase.“For Roche, the acquisition extends its reach into the fast-growing respiratory market, a therapy franchise from which the company derives only a small fraction of its sales. The deal will broaden Roche’s portfolio, which currently consists of marketed products Xolair and Pulmozyme for treating asthma and cystic fibrosis, respectively.“InterMune stated that it has been charging about $40,000 a year per patient for pirfenidone outside the US. The price reflects the value that the medicine brings, since IPF affects about 100,000 people in the US and has been an especially daunting medical target, with patients often dying three to five years after diagnosis. Roche probably considered these factors when it decided to purchase InterMune, giving the company an opportunity to charge a high price for a new drug indicated to treat a disease with poor diagnosis.”


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: